Omeros (NASDAQ:OMER) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research report sent to investors on Thursday morning.

A number of other research analysts also recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Thursday, February 20th. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

OMER stock opened at $8.42 on Thursday. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The business’s 50 day moving average price is $8.80 and its two-hundred day moving average price is $7.17. The company has a market capitalization of $487.94 million, a price-to-earnings ratio of -3.65 and a beta of 2.03.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Truvestments Capital LLC lifted its position in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in Omeros in the 4th quarter valued at approximately $46,000. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management lifted its position in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.